Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 64 от 100

Предстои набиране Фаза 1

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

Triple Negative Breast Cancer (TNBC) Colorectal Cancer Urothelial Cancer

This is a Phase 1a/1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory/resistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.

Начало: 01.09.2026 Край: 01.01.2030 Възраст: от 18 г.

Context Therapeutics Inc. NCT07545122

Предстои набиране Фаза 2

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

TNBC - Triple-Negative Breast Cancer Breast Cancer

Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance. RT, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2; Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.

Начало: 01.06.2026 Край: 01.07.2033 Възраст: от 18 г.

United States Stephen Shiao NCT07015853

Предстои набиране

BfedBwell INSPIRE Pilot

Cancer Survivorship Overweight , Obesity

This single-arm pilot study will evaluate the feasibility and acceptability of a comprehensive survivorship lifestyle intervention addressing nutrition, exercise, sleep health, and stress management. The intervention integrates the BfedBwell survivorship nutrition program with the BfitBwell clinical exercise oncology program. The augmented BfedBwell program includes: (1) a core education curriculum, (2) 1:1 counseling with a registered dietitian, (3) behavioral skills development, (4) group support, and (5) commercially available wearable technology and smart scales for self-monitoring of physical activity, sleep, and body weight.

Начало: 01.06.2026 Край: 01.03.2027 Възраст: 18–75 г.

United States University of Colorado, Denver NCT07446595

Предстои набиране

Barriers and Facilitators of Persistence With Adjuvant Osimertinib

Non-small Cell Lung Cancer

This is a cross-sectional, non-interventional qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage NSCLC in China. Approximately 100 participants will be enrolled, comprising around 85 patients and 15 physicians. All participants will be interviewed online or in-person using a COM-B (Capability, Opportunity, Motivation - Behaviour) based guide. Interviews will be conducted in waves, recorded, transcribed, and analysed using both deductive and inductive methods.

Начало: 01.06.2026 Край: 15.08.2026 Възраст: от 18 г.

China AstraZeneca NCT07542210

Предстои набиране Фаза 1/2

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

Solid Tumor Malignancies Testicular Cancer Head and Neck Cancer Thoracic Cancer

The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing hearing loss has been well established in children and is approved for use in the pediatric and young adult population. However, information in adult patients is limited. As most cisplatin is administered in the adult population, this investigation would be of benefit.

Начало: 30.05.2026 Край: 30.04.2028 Възраст: от 18 г.

United States University of Arizona NCT07407582

Предстои набиране

Ambispective Validation of the Odesa Criteria 2026 (OC26): A Flexible Point-Based System for Diagnosis of Autoimmune Pancreatitis.

Autoimmune Pancreatitis IgG4-Related Diseases Pancreatic Cancer Chronic Pancreatitis

Approval Number protocol 020237 Board Name Ethics Committee of the Military Medical Clinical Center of the Southern Region. Board Affiliation Military Medical Clinical Center of the Southern Region, Ukraine. Board Contact Information Phone: +380 (50) 316-10-54)

Начало: 01.05.2026 Край: 31.12.2026 Възраст: от 18 г.

Military Medical Clinical Center of the Southern Region NCT07536841

Предстои набиране

Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.

Lymph Node Cancer Cutaneous T-cell Lymphoma

Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.

Начало: 01.05.2026 Край: 01.05.2027 Възраст: от 18 г.

Costa Rica Caja Costarricense de Seguro Social NCT07538960

Предстои набиране

Safety Evaluation of Bioactive Glass Based Bone Cement Combined With Ultrasound in Implantation for Metastatic Bone Tumors

Advanced Cancer Pain

This study is evaluating the safety of using bioactive glass-containing bone cement combined with ultrasound during surgery for patients with metastatic bone tumors. We aim to see if this treatment can be safely applied to stabilize the bone and reduce pain, without causing unexpected side effects. All participants will receive standard care plus the study treatment, and we will closely monitor them during and after the procedure to check for any safety concerns.

Начало: 01.05.2026 Край: 30.04.2028 Възраст: 18–80 г.

Liao Yun NCT07540468

Предстои набиране

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

HCC - Hepatocellular Carcinoma TP53 Gene Mutation Unresectable Resistant Cancer

This study aims to evaluate the effectiveness and safety of a combination therapy with Fuxinqibai monoclonal antibody, Tislelizumab, and Lenvatinib in patients with advanced, unresectable TP53-mutated hepatocellular carcinoma (HCC) who have previously failed systemic immunotherapy. Eligible patients will receive: Fuxinqibai 200 mg IV every 3 weeks Tislelizumab 200 mg IV every 3 weeks Lenvatinib 8 mg (≤60 kg) or 12 mg (\>60 kg) orally once daily Treatment will continue until disease progression, unacceptable toxicity, start of a new anticancer therapy, withdrawal of consent, or other protocol-defined reasons. Tumor response will be evaluated by RECIST v1.1 every 6 weeks, and confirmed after 4 weeks if response is observed. Safety will be monitored through adverse events and laboratory tests, graded according to NCI CTCAE v5.0. After treatment ends, patients will be followed every 6 weeks for tumor assessment and every 12 weeks for survival, until death, loss to follow-up, or withdrawal of consent. Primary Objective: To assess the objective response rate (ORR) of the combination therapy. Secondary Objectives: To evaluate overall efficacy, safety, and explore potential biomarkers predicting treatment response.

Начало: 01.05.2026 Край: 01.06.2027 Възраст: от 18 г.

Tongji Hospital NCT07535840

Предстои набиране Фаза 1

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

Advanced Solid Tumors Colorectal Cancer (CRC) Non-Small Cell Lung Cancer Uterine Cancer +2

The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are: * What is the safe dose of KQB368 as a monotherapy? * Does KQB368 decrease the size of the tumor? * What happens to KQB368 in the body? Participants will: * Take KQB368 orally daily in 21-day cycles * Return to the study site about 7 times in the first 5 weeks, and then once at the beginning of every 21-day cycle after that

Начало: 01.05.2026 Край: 01.12.2029 Възраст: от 18 г.

Kumquat Biosciences Inc. NCT07542704

Предстои набиране Фаза 3

SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

Rectal Adenocarcinoma High-Risk Cancer MSS

To explore the efficacy and safety of an intensified treatment regimen consisting of short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with precise targeted therapy (based on RAS/BRAF status: cetuximab for wild-type, bevacizumab for mutant) and a PD-1 monoclonal antibody, compared with short-course radiotherapy followed by mFOLFOX6 chemotherapy alone, in high-risk locally advanced pMMR/MSS rectal adenocarcinoma through a prospective, randomized controlled phase III clinical study, providing high-level evidence-based medical evidence to establish a superior neoadjuvant treatment strategy for this population.

Начало: 30.04.2026 Край: 30.04.2029 Възраст: 18–75 г.

China Sixth Affiliated Hospital, Sun Yat-sen University NCT07549399

Предстои набиране Фаза 1/2

Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma

Head & Neck Cancer

This is a prospective, single-arm, Phase II clinical trial designed to evaluate the efficacy and safety of vibecotamab combined with putelimab in the treatment of locally advanced laryngeal carcinoma.

Начало: 23.04.2026 Край: 23.04.2031 Възраст: 18–80 г.

Tang-Du Hospital NCT07538206

Предстои набиране

Investigation of Digital Media Use in Patients Receiving Chemotherapy

Cancer Chemotherapy

This study aims to examine digital media use and eHealth literacy among patients receiving chemotherapy. Digital media has become an important tool for accessing health information, communicating with healthcare providers, and supporting self-management. This observational study will be conducted with adult patients receiving chemotherapy in an outpatient setting. Data will be collected using a sociodemographic information form and the eHealth Literacy Scale (eHEALS). The findings are expected to contribute to a better understanding of digital media use and digital health literacy levels in chemotherapy patients.

Начало: 20.04.2026 Край: 20.05.2026 Възраст: 18–67 г.

Turkey (Türkiye) Fenerbahce University NCT07501871

Предстои набиране

The Comparison Between M-E-BCS and C-O-BCS.

Breast Cancer

This study is a multicenter, open-label, randomized controlled trial. The study aims to evaluate differences in operative efficiency (e.g., operative time), economic effect, surgical safety (e.g., surgical complication rates), postoperative aesthetics (e.g., BREAST-Q scores, Harris scores, SCAR-Q scores and Ueda scores), and oncological safety (e.g., margin status, no local recurrence survival) between patients undergoing M-E-BCS and patients undergoing C-O-BCS.

Начало: 01.04.2026 Край: 31.12.2032 Възраст: 18–70 г.

China Du Zhenggui NCT07539545

Предстои набиране Фаза 1

A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function

Lung Cancer

Evaluation of the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects with Impaired Liver Function versus Normal Liver Function

Начало: 01.04.2026 Край: 01.09.2027 Възраст: 18–65 г.

China Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NCT07538973

Предстои набиране

The Hugo RAS Colorectal Collaborative

Colorectal Surgery Robotic Surgery ColoRectal Cancer and Inflammatory Bowel Disease

The Hugo RAS Colorectal Collaborative (HRCC) is an international, multicenter dataset of patients undergoing colorectal surgery using the Hugo RAS system. The registry aims to analyze short and long-term outcomes to provide real-world evidence on the safety and effectiveness of the system.

Начало: 01.04.2026 Край: 01.06.2029 Възраст: от 18 г.

IRCCS Azienda Ospedaliero-Universitaria di Bologna NCT07541352

Предстои набиране

Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada

Asthma Chronic Obstructive Pulmonary Disease (COPD) Lung Cancer

Wildfire smoke (WFS) is the leading climate-related risk in Canada and the main source of harmful air pollution. While short-term breathing problems caused by smoke are well known, there is limited knowledge on how repeated exposure contributes to long-term lung disease. This study is a controlled human exposure to varying concentrations of WFS in a safe setting. By comparing the effects of different concentrations, this research will improve understanding of health impacts, identify who may be most vulnerable to exposures, and explore biological changes that could lead to chronic illness.

Начало: 01.04.2026 Край: 31.08.2030 Възраст: 19–80 г.

University of British Columbia NCT07536178

Предстои набиране

Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology

Small Cell Lung Cancer Head and Neck Cancer Malignant Pleural Mesothelioma

This is an ancillary laboratory study to collect and bank blood and tissue samples. The biospecimens collected for this study will be invaluable for future research into predictive biomarkers and genomic alterations and their correlation with clinical outcomes.

Начало: 01.04.2026 Край: 01.04.2029 Възраст: от 18 г.

University of Kansas Medical Center NCT07550049

Предстои набиране Фаза 1

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

Colorectal Cancer Gastric Adenocarcinoma Esophageal Adenocarcinoma Gastroesophageal Adenocarcinoma

This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \[CAR\] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.

Начало: 01.04.2026 Край: 01.04.2046 Възраст: от 18 г.

United States Dispatch Biotherapeutics NCT07544589

Предстои набиране

Surgical Glove Compression to Prevent Paclitaxel Neuropathy

Paclitaxel-Induced Peripheral Neuropathy Breast Cancer Surgical Glove

This study aims to evaluate the effect of surgical glove compression as a prophylactic method to prevent paclitaxel-induced peripheral neuropathy. Participants will be randomly assigned to two groups: one receiving standard care, and the other receiving prophylactic surgical glove compression. The study will compare the development, severity of neuropathy in the hands and fingers, and its impact on quality of life.

Начало: 26.03.2026 Край: 26.03.2027 Възраст: 18–80 г.

Turkey (Türkiye) Necmettin Erbakan University NCT07504770

1 … 62 63 64 65 66 … 100